Tag: FDA approves Keytruda as adjuvant treatment for kidney cancer

The cancer immunotherapy drug Keytruda (pembrolizumab), was approved Thursday by the U.S. Food and Drug Administration (FDA) to help in the fight against renal cell carcinoma (RCC), according to a news release from Merck, the drug maker of Keytruda. Keytruda is a medicine that is typically used to treat advanced types of cancers such as lung cancer and melanoma, by working with a patient’s immune system.null…